Thrombosis is one of the most serious complications of cardiovascular diseases and the most important factor of death and disability in these patients. Studies have shown that platelet activation and aggregation are the initiating factors of thrombosis in the body and one of the most critical components of the thrombosis process. Antiplatelet drugs such as aspirin, platelet P2Y12 receptor antagonists (ticlopidine, clopidogrel, prasugrel, ticagrelor, etc.) and platelet glycoprotein II b/IIIa receptor antagonists can significantly reduce the risk of atherosclerotic thrombosis. Currently, antiplatelet therapy is widely used in the primary and secondary prevention of cardiovascular disease. Aspirin and clopidogrel are the recommended antiplatelet agents for secondary prevention of ischemic cerebrovascular disease in China and abroad.11 J. The Chinese Guidelines for the Management of Acute Ischemic Stroke 2010 states that the efficacy of aspirin within 48 h after stroke was studied in a large sample of trials (the Chinese Acute Stroke Trial and the International Stroke Trial), and the results showed that aspirin significantly reduced the rate of death or disability at the end of the follow-up period. The results showed that aspirin significantly reduced the rate of death or disability at the end of follow-up, reduced recurrence, and only mildly increased the risk of symptomatic intracranial hemorrhage. It is recommended that oral aspirin 150-300 mg/d should be given as soon as possible after the onset of stroke in patients with ischemic stroke who do not meet the indications for thrombolysis and for whom there are no contraindications (Class I recommendation, Level A evidence). For thrombolytic therapy, antiplatelet agents such as aspirin should be started 24 h after thrombolysis (Class I recommendation, Level B evidence). The Chinese Guidelines for Secondary Prevention of Ischemic Stroke and TIA 20109 and the {201 1 American Heart Association (AHA)/American Stroke Association (ASA) Guidelines for Secondary Prevention of Stroke clearly recommend that antiplatelet agents are recommended in most cases for patients with non-cardiogenic embolic ischaemic stroke or TIA to reduce the incidence of recurrence and other cardiovascular events (Class I recommendation, Class A evidence). Class A evidence). The guidelines also recommend a standard treatment regimen of combined aspirin and clopidogrel antiplatelet therapy for patients after endovascular stenting.1341 However, the guidelines do not provide detailed and specific instructions on the timing and dosage of administration. In 201 1, the Cerebrovascular Disease Group of the Chinese Medical Association Neurology Branch promulgated the Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease in China, which described the perioperative antiplatelet therapy for endovascular interventions in cerebrovascular disease as follows: To prevent the occurrence of platelet emboli during surgery, aspirin and clopidogrel should be combined in the preoperative days. The dose of each antiplatelet agent varies between operators. There is no consensus on the safety, dosage and timing of drug combinations of antiplatelet agents. The current regimen used in most centers is that patients who have received long-term aspirin therapy before the procedure should be given 100-300 mg daily before the intervention; patients who have not taken aspirin in the past should be given 300 mg at least 2 h before the intervention, preferably 24 h before .